Targets › HLA-DPB1
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Hematology, Other; next expected readout Jul 2027.
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. (UniProt, P04440)
Open in Phaseline: the race on HLA-DPB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nantes University Hospital | CTL 19 HLA-DPB1-specific T cell clone therapy targeting HLA-DPB1*04:01 expressing hematological m | HLA-DPB1 | Phase 3 | Ankle Fractures; Haematologic Disease | Jul 2027 |
Ankle Fractures (1) Haematologic Disease (1)
other (1)
Nantes University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.